Press Releases
Filters
March 30, 2022
Sesame Workshop and Viatris Launch New Emotional Health and Wellbeing Resources for Families Grappling with Effects of COVID-19
March 16, 2022
Viatris Inc. Announces Receipt of the First FDA Approval for Generic Version of Symbicort® Inhalation Aerosol, Breyna™ (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), in Partnership with Kindeva
February 28, 2022
Viatris Reports Strong Fourth Quarter and Full-Year 2021 Financial Results; Issues 2022 Financial Guidance; Completes Comprehensive Strategic Review; Unveils Plan to Reshape the Company for the Future; Announces Combination of its Biosimilars Portfolio with Biocon Biologics in Exchange for up to $3.335 Billion Representing an Attractive Multiple to Viatris of 16.5x the Company's Biosimilars 2022E Adjusted EBITDA(1), the First in a Series of Expected Initiatives Anticipated to Unlock up to an Add
February 4, 2022
Viatris to Host Virtual Investor Event and Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022
February 3, 2022
Viatris is First to Receive FDA Approval of Generic Restasis® (Cyclosporine Ophthalmic Emulsion 0.05%) to Treat Dry Eye Disease
Displaying 91 - 100 of 137